Loading…
← CockpitCompetitor Analysis › VIMIAN.ST Vimian Group ABOpen in the cockpit ↗

Vimian Group ABVIMIAN.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Biotechnology

Swedish animal-health group providing veterinary diagnostics, specialty pharma and pet-care products, built through acquisitions.

≈ A smaller, roll-up version of IDEXX Laboratories/ZoetisMomentum leader 96
Mkt cap
$2.26B
US dollars, full cap
Free float
29%
of shares outstanding
$/day
$1.63M
20-day average traded
Fwd P/E
38.4×
forward earnings
ROIC−WACC
-0.4 pp
WACC 7.3%
Hurdle
-31 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · SEKSEK 43.50
1D+3.6%
1W+3.6%
1M+14.3%
3M+24.8%
6M+50.8%
YTD+43.4%
1Y+42.0%
ATR %2.1%
52w lowhigh0.1% off high

What Vimian does

Swedish animal-health group providing veterinary diagnostics, specialty pharma and pet-care products, built through acquisitions.

In one line: A smaller, roll-up version of IDEXX Laboratories/Zoetis.

Products and services

  • Veterinary diagnostics
  • Specialty veterinary pharmaceuticals
  • Pet care/nutrition products

Customers

  • Veterinary clinics
  • Pet owners (indirect)

Where it sits in the supply chain

  • Health Care
  • Animal health
  • Veterinary diagnostics + specialty…

What could go right

  • Pet-ownership and vet-spend growth
  • Bolt-on acquisitions

What could go wrong

  • Integration risk from serial M&A
  • Competition from larger diagnostics players

Moat: narrow (installed base, customer qualification). Niche diagnostics/specialty products with vet-clinic relationships, in a market led by larger scaled players.

Headquarters: Stockholm, Sweden · Founded: 2021 · Employees: 1,300

Named competitors

Vimian at a glance

Size Vimian (VIMIAN.ST) is a Sweden Health Care company (Biotechnology) with a market value of $2.26B, the 72nd largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 43.50 on 18 Nov 2026.

Performance Over six months the shares gained 50.8%, against -10.8% for the median peer and +2.8% for the Sweden market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue grew 8.0% over the last twelve months (peer median +5.5%); the operating margin is 19.2% (peer median -19.9%).

Valuation It trades at 38.4× forward earnings against a peer median of 18.1× (3rd most expensive of 6).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +44%, so the hurdle is -31 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.4 points below its cost of capital (7.3% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026VIMIAN.ST 154Peer median 92
Six months, rebased to 100: Vimian against the median of its 20 peers (local-currency closes).

Vimian financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 5.09BSEK 4.70BSEK 4.29BSEK 3.81BSEK 2.99B
Revenue growth—+10%+13%+27%—
Gross profitSEK 977MSEK 799MSEK 690MSEK 596MSEK 570M
EBITDASEK 1.44BSEK 1.22BSEK 1.08BSEK 963MSEK 860M
Net incomeSEK 428MSEK 346MSEK 212MSEK 113M-SEK 71.7M
Free cash flowSEK 1.03BSEK 1.07BSEK 592M-SEK 419MSEK 207M
Capital expenditureSEK 234MSEK 167MSEK 162MSEK 171MSEK 110M
Total debtSEK 3.18BSEK 2.58BSEK 2.67BSEK 3.49BSEK 2.46B

Quarterly statements and history in the cockpit →

Vimian competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%302440LKFTRCUSPHVS300255BEAMCLDXZEALPVLA300676ALMRIMNMXNCRMRVIMBXVIMIAN.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Vimian is the large dot.

Fundamentals: revenue growth against valuation

-40%-20%0%+20%0×100×200×300×ZEAL300676300142AUPH688278VIMIAN.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Vimian is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300142AUPH688278VIMIAN.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Vimian is the large dot.

Vimian competitors and peer comparison

Head to head with its named competitors (VIMIAN.ST vs IDXX vs ZTS vs ELAN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Vimian VIMIAN.ST$2.26B+51%+8%19%38.4×13.4%
Idexx Laboratories IDXX$55.0B+26%+12%32%42.9×29.0%
Zoetis ZTS$34.8B+7%+1%37%13.8×-2.9%
Elanco Animal Health ELAN$13.3B+28%+12%8%21.5×32.9%
Virbac VIRP.PA$3.20B-4%+4%15%16.6×5.8%
Vetoquinol VETO.PA$1.10B+19%-1%15%15.5×-3.6%

How Vimian compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Vimian against its 20 peers (data as of 18 Nov 2026)
MeasureVIMIAN.STPeer medianRank in peer set
1-month return+14.3%-4.9%4th highest of 21
6-month return+50.8%-10.8%5th highest of 20
Distance from 52-week high-0.1%-35.4%highest of 21
Revenue growth (TTM)+8.0%+5.5%9th highest of 17
Operating margin19.2%-19.9%5th highest of 15
Forward P/E38.4×18.1×3rd most expensive of 6
Growth the price implies (Req g, 7 yrs)13.4%3.5%2nd most demanding of 4
Growth delivered (Del g)+44.5%+36.0%highest of 4
Hurdle (Req g minus delivered)-31.1 pp-36.6 pp2nd most demanding of 4
ROIC minus cost of capital-0.4 pp-11.0 pp5th highest of 12
EV / EBITDA17.8×n/a—
Net debt / EBITDA1.8×-2.6×2nd most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Vimian VIMIAN.STSweden$2.26B+51%+8%19%38.4×13.4%+44.5%
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%n/an/an/a
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%n/an/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%n/an/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%n/an/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%n/an/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%7.2×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%126.7×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%n/an/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/an/an/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%348.7×29.5%-3.8%
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%18.1×3.5%+41.4%
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%15.0×-0.6%+36.0%
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Xencor XNCRUnited States$2.58B+204%+34%-73%n/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%n/an/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a

Questions

Who are Vimian's main competitors?
Named competitors: IDEXX Laboratories (IDXX), Zoetis (ZTS), Heska Corporation (private or unlisted), Elanco Animal Health (ELAN), Virbac (VIRP.PA), Vetoquinol (VETO.PA). The cockpit's measured peer set (industry) also includes SKBS (302440.KS), Lakefront Biotherapeutics (LKFT.AS), Arcus Biosciences (RCUS), Pharvaris (PHVS), Hebei Changshan Biochemical Pharmaceutical (300255.SZ), Beam Therapeutics (BEAM).
Is Vimian expensive compared with its peers?
On forward p/e it trades at 38.4× against a peer median of 18.1×, 3rd most expensive of 6 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +44%, so the hurdle is -31 pp: the price already allows for a slowdown.
How has Vimian stock performed?
Over six months to 18 Nov 2026 the shares returned +50.8% against -10.8% for the median peer; over one year +42.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.